Literature DB >> 26025325

Predicting a response to FOLFIRINOX in pancreatic cancer.

Ryan D Nipp1, David P Ryan2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26025325      PMCID: PMC4609560          DOI: 10.1093/jnci/djv175

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Authors:  Jason E Faris; Lawrence S Blaszkowsky; Shaunagh McDermott; Alexander R Guimaraes; Jackie Szymonifka; Mai Anh Huynh; Cristina R Ferrone; Jennifer A Wargo; Jill N Allen; Lauren E Dias; Eunice L Kwak; Keith D Lillemoe; Sarah P Thayer; Janet E Murphy; Andrew X Zhu; Dushyant V Sahani; Jennifer Y Wo; Jeffrey W Clark; Carlos Fernandez-del Castillo; David P Ryan; Theodore S Hong
Journal:  Oncologist       Date:  2013-05-08

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-11-27       Impact factor: 91.245

4.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

5.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Authors:  Brian A Boone; Jennifer Steve; Alyssa M Krasinskas; Amer H Zureikat; Barry C Lembersky; Michael K Gibson; Ronald G Stoller; Herbert J Zeh; Nathan Bahary
Journal:  J Surg Oncol       Date:  2013-09       Impact factor: 3.454

6.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

7.  Whole genomes redefine the mutational landscape of pancreatic cancer.

Authors:  Nicola Waddell; Marina Pajic; Ann-Marie Patch; David K Chang; Karin S Kassahn; Peter Bailey; Amber L Johns; David Miller; Katia Nones; Kelly Quek; Michael C J Quinn; Alan J Robertson; Muhammad Z H Fadlullah; Tim J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Craig Nourse; Ehsan Nourbakhsh; Shivangi Wani; Peter J Wilson; Emma Markham; Nicole Cloonan; Matthew J Anderson; J Lynn Fink; Oliver Holmes; Stephen H Kazakoff; Conrad Leonard; Felicity Newell; Barsha Poudel; Sarah Song; Darrin Taylor; Nick Waddell; Scott Wood; Qinying Xu; Jianmin Wu; Mark Pinese; Mark J Cowley; Hong C Lee; Marc D Jones; Adnan M Nagrial; Jeremy Humphris; Lorraine A Chantrill; Venessa Chin; Angela M Steinmann; Amanda Mawson; Emily S Humphrey; Emily K Colvin; Angela Chou; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Pettitt; Neil D Merrett; Christopher Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Nigel B Jamieson; Janet S Graham; Simone P Niclou; Rolf Bjerkvig; Robert Grützmann; Daniela Aust; Ralph H Hruban; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Massimo Falconi; Giuseppe Zamboni; Giampaolo Tortora; Margaret A Tempero; Anthony J Gill; James R Eshleman; Christian Pilarsky; Aldo Scarpa; Elizabeth A Musgrove; John V Pearson; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2015-02-26       Impact factor: 49.962

8.  Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.

Authors:  Guang Xu; Wanghai Zhang; Margaret K Ma; Howard L McLeod
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

9.  A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Authors:  Peter J Hosein; Jessica Macintyre; Carolina Kawamura; Jennifer Cudris Maldonado; Vinicius Ernani; Arturo Loaiza-Bonilla; Govindarajan Narayanan; Afonso Ribeiro; Lorraine Portelance; Jaime R Merchan; Joe U Levi; Caio M Rocha-Lima
Journal:  BMC Cancer       Date:  2012-05-29       Impact factor: 4.430

10.  CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.

Authors:  S Guichard; C Terret; I Hennebelle; I Lochon; P Chevreau; E Frétigny; J Selves; E Chatelut; R Bugat; P Canal
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  1 in total

1.  Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis.

Authors:  Jie Li; Zhonghu Li; Peng Jiang; Minjie Peng; Xi Zhang; Kai Chen; Hui Liu; Huaqiang Bi; Xiangde Liu; Xiaowu Li
Journal:  J Exp Clin Cancer Res       Date:  2018-07-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.